The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria Malaria is a serious and potentially fatal paras...
“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
“We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bemped...
The innovative partnership seeks to revolutionize decentralized genomic testing, offering swift turnaround times to identify individuals wh...
In an effort to bridge testing gaps and facilitate targeted therapies for EOC patients, Labcorp conducted two seminal studies, illustrating the profound im...
Optinose, a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy conditions, has achieved a significant milestone ...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
Novo Holdings, a leading global life sciences investor, has announced its participation in a significant €30M Series A financing round for Asgard Ther...
In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal a...
Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancr...
With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing can...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...
The newly unveiled suite of Precision Dx Products includes the Twist Precision Prep and Enrichment Dx Kit, the Twist Precision Exome Dx Panel, and ...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announ...
© 2025 Biopharma Boardroom. All Rights Reserved.
